Retatrutide: One Molecule, Three Receptor Jobs at Once

Abstract — the short version

Retatrutide, also designated LY3437943, is an investigational peptide — not yet approved anywhere — being tested in Phase 3 trials as of mid-2026 ^[16]. It is a triple agonist: one molecule that switches on three different hormone receptors instead of just one. Two of its jobs are shared with other metabolic-hormone peptides: suppressing appetite and boosting insulin release. Its third job is unique to this molecule: increasing energy expenditure through a controlled glucagon-receptor effect.

In a 48-week Phase 2 trial, the highest studied dose produced substantially greater average body-weight reduction than placebo ^[19]. Everything on this page is drawn from published Phase 1 and Phase 2 data; no dose here is a recommendation, and this compound has no approved use anywhere.

Definition and structure

Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone, acylated with a C20 fatty-diacid arm for albumin binding and an extended circulating half-life (molecular formula C221H342N46O68, free acid). 2024 cryo-EM structures resolved how the molecule engages all three of its target receptors at atomic resolution, showing it is roughly 8.9-fold more potent than the native hormone at one receptor (GIP) but weaker than the native hormones at the other two (glucagon and GLP-1) ^[17] — a molecule engineered to engage three receptors differentially, not equally.

Mechanism of action

Retatrutide inherits the appetite-suppression and insulin-secretion pharmacology of two receptor arms — the glucagon-like peptide-1 receptor and the glucose-dependent insulinotropic polypeptide receptor — and adds a third: controlled activation of the glucagon receptor. Glucagon signaling normally tells the liver to release stored sugar, but in combination with the other two arms it instead appears to increase energy expenditure through fat-tissue heat production and fatty-acid burning, with minimal net glucose elevation ^[16]. In effect, two arms reduce how much is eaten while the third increases how much energy is burned — acting on both sides of the body's energy balance at once. Its identified mechanism targets are the GLP-1 receptor, the GIP receptor, and the glucagon receptor.

Evidence review

A 2025 review synthesizes retatrutide's triple-agonist pharmacology and Phase 1/2 data, characterizing weight loss of up to roughly 24% as a step-change versus prior hormone-agonist therapies and reviewing its gastrointestinal and heart-rate safety profile alongside the ongoing Phase 3 program ^[16]. 2024 cryo-EM work resolved retatrutide's triple-agonist binding at high resolution and quantified its relative potency at each of the three receptors compared with the native hormones ^[17].

A 48-week Phase 2 substudy in 98 adults with obesity or overweight and metabolic-associated fatty liver disease found the highest dose reduced liver fat by 82.4% at 24 weeks, with 86% of participants reaching normal liver-fat levels, and reductions sustained to 48 weeks ^[18]. A 48-week Phase 2 obesity trial in 338 adults found the highest dose produced a mean body-weight change of -24.2% versus -2.1% with placebo; gastrointestinal adverse events were dose-related and mostly mild-to-moderate, and a dose-dependent heart-rate increase peaked around 24 weeks ^[19]. A 36-week Phase 2 trial in 281 adults with type 2 diabetes found the highest dose lowered a blood-sugar marker (HbA1c) by 2.02 percentage points at 24 weeks and reduced body weight by 16.94% at 36 weeks versus placebo, with no severe low-blood-sugar events and no deaths ^[20].

Reported effects, cautions and safety profile

People using retatrutide for research purposes in peptide communities describe effects broadly consistent with the trial data, plus some features attributed to its unique third receptor arm; this is anecdotal, not clinical evidence, drawn from online community self-reports with no confirmed doses or clinical oversight. Reported benefits include near-total quieting of food-related thoughts, rapid weight reduction, and a mild sensation of warmth some attribute to the glucagon-receptor arm's effect on energy expenditure. Reported adverse effects include nausea peaking hours after a dose, an awareness of a faster resting heart rate, sulfur-smelling burps, fatigue, and constipation.

Cited cautions from the clinical literature: retatrutide remains an unapproved investigational compound, so material obtained outside a registered trial cannot be verified for identity, purity, or sterility ^[16][19]. Gastrointestinal adverse events were dose-related and the leading reason for discontinuation in the Phase 2 obesity trial ^[19]. A dose-dependent increase in resting heart rate was observed, peaking around 24 weeks ^[19]. Combined with insulin or sulfonylurea medications, the compound's insulin-boosting action can raise the risk of low blood sugar, requiring monitoring and dose adjustment of those other medications ^[20]. Body-composition analyses associated with the Phase 2 program note that weight loss includes reductions in lean mass alongside fat mass, a general feature of this hormone-receptor class. Long-term safety and the durability of effect after stopping remain unknown while Phase 3 trials are still underway ^[16].

Position within the functional taxonomy

Retatrutide's job is whole-body metabolic-hormone regulation — appetite and energy balance — the broadest-scope job on this desk, in contrast with KPV's tissue-local anti-inflammatory action or PT-141's central-nervous-system signaling. See the full lineup on the comparison page, or read the lead compound, thymosin alpha-1.